|Day Low/High||126.33 / 127.62|
|52 Wk Low/High||109.32 / 129.00|
The $33 million settlement was announced by the attorney general on behalf of 42 states and the District of Columbia.
Doug Kass shares his thoughts on Treasury notes and bonds, and offers some other observations.
South Korea's Samsung Bioepis is looking to sell its version of the drug in the U.S.
Hershey is among more than 100 stocks and funds going ex-dividend in the week ahead.
Company officials conducted a pharmaceutical business review meeting with industry analysts on Wednesday.
- Company expects more than 10 new blockbuster products to launch or file for regulatory approval by 2021
Citigroup had a 'thoughtful' research piece on Pfizer, but downgrading it partly based on 'transaction risk' seems unreasonable, Cramer said.
Shares of JNJ have been moving well since the opening bell and are now well above the April peak.
Medtronic, J&J and Cardinal Health appear poised to benefit from an aging U.S. population, say investment experts.
JPMorgan analyst Michael Weinstein contended that the negative sentiment encompassing the stock might be overdone.
Here are Monday's top research calls, including upgrades for Cisco Systems and Johnson & Johnson, and downgrades for J.C. Penney and Tesla.
Female representation among the top 10% of earners at the NAFE top companies increased 2% to 41%, the highest since 2013.
YouTube is making a push into original content after suffering from a boycott from top advertisers in March.
Johnson & Johnson is standing behind its product.
The Cordis and Medtronic acquisitions are meant to shield Cardinal from the pricing swings of drug distribution.
Here's the reason we can justify trades like GOOGL and SBUX last week.
Investors should consider factoring in goodwill when they are examining the value of a stock because it can often predict the outlook of a company, especially serial acquirers.
Morgan Stanley leads the banks, while Kirkland & Ellis tops the law firms.
Let's pull the band aid off the charts, carefully.
Biotech investors should keep a close eye on the progress in this huge potential market.
Pet costs are seen surging, as are several other top household categories.